Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial.
Cole PD, McCarten KM, Pei Q, Spira M, Metzger ML, Drachtman RA, Horton TM, Bush R, Blaney SM, Weigel BJ, Kelly KM. Cole PD, et al. Among authors: mccarten km. Lancet Oncol. 2018 Sep;19(9):1229-1238. doi: 10.1016/S1470-2045(18)30426-1. Epub 2018 Aug 16. Lancet Oncol. 2018. PMID: 30122620 Free PMC article. Clinical Trial.
Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group.
Parikh RR, Kelly KM, Hodgson DC, Hoppe BS, McCarten KM, Karolczuk K, Pei Q, Wu Y, Cho SY, Schwartz C, Cole PD, Roberts K. Parikh RR, et al. Among authors: mccarten km. Int J Radiat Oncol Biol Phys. 2022 Mar 15;112(4):890-900. doi: 10.1016/j.ijrobp.2021.10.152. Epub 2021 Nov 9. Int J Radiat Oncol Biol Phys. 2022. PMID: 34767937 Free PMC article. Clinical Trial.
Durable remission for four pediatric patients with high-risk relapsed classical Hodgkin lymphoma treated with brentuximab vedotin plus gemcitabine but without autologous stem cell transplantation: A report from the Children's Oncology Group.
Buhtoiarov IN, Mba NI, Santos CDL, McCarten KM, Metzger ML, Pei Q, Bush R, Baker K, Kelly KM, Cole PD. Buhtoiarov IN, et al. Among authors: mccarten km. Pediatr Blood Cancer. 2022 Jun;69(6):e29649. doi: 10.1002/pbc.29649. Epub 2022 Mar 26. Pediatr Blood Cancer. 2022. PMID: 35338689 Free PMC article.
Early [¹⁸F]fluorodeoxyglucose positron emission tomography-based response evaluation after treatment with gemcitabine and vinorelbine for refractory Hodgkin disease: a children's oncology group report.
Cole PD, McCarten KM, Drachtman RA, Alarcon Pd, Chen L, Trippett TM, Schwartz CL. Cole PD, et al. Among authors: mccarten km. Pediatr Hematol Oncol. 2010 Nov;27(8):650-7. doi: 10.3109/08880018.2010.504250. Pediatr Hematol Oncol. 2010. PMID: 20863157 Free PMC article.
A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group study.
Horton TM, Drachtman RA, Chen L, Cole PD, McCarten K, Voss S, Guillerman RP, Buxton A, Howard SC, Hogan SM, Sheehan AM, López-Terrada D, Mrazek MD, Agrawal N, Wu MF, Liu H, De Alarcon PA, Trippet TM, Schwartz CL. Horton TM, et al. Br J Haematol. 2015 Jul;170(1):118-22. doi: 10.1111/bjh.13388. Epub 2015 Apr 1. Br J Haematol. 2015. PMID: 25833390 Free PMC article. Clinical Trial.
Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: A report from the Children's Oncology Group.
Keller FG, Castellino SM, Chen L, Pei Q, Voss SD, McCarten KM, Senn SL, Buxton AB, Bush R, Constine LS, Schwartz CL. Keller FG, et al. Among authors: mccarten km. Cancer. 2018 Aug 1;124(15):3210-3219. doi: 10.1002/cncr.31519. Epub 2018 May 8. Cancer. 2018. PMID: 29738613 Free PMC article. Clinical Trial.
Prognostic value of baseline metabolic tumor volume in children and adolescents with intermediate-risk Hodgkin lymphoma treated with chemo-radiation therapy: FDG-PET parameter analysis in a subgroup from COG AHOD0031.
Milgrom SA, Kim J, Chirindel A, Kim J, Pei Q, Chen L, Buxton A, Kessel S, Leal J, McCarten KM, Hoppe BS, Wolden SL, Schwartz CL, Friedman DL, Kelly KM, Cho SY. Milgrom SA, et al. Among authors: mccarten km. Pediatr Blood Cancer. 2021 Sep;68(9):e29212. doi: 10.1002/pbc.29212. Epub 2021 Jul 10. Pediatr Blood Cancer. 2021. PMID: 34245210 Free PMC article.
55 results